Biotech Archives - Page 111 of 795

2 minute read

Merck Posts Surprise Quarterly Profit Against An Expected Loss, Oncology And Vaccines Drive Growth

February 1, 11:43 AM

Merck reports fourth quarter 2023 sales of $14.63 billion, a 6% YoY increase, beating estimates. Explore oncology, vaccines, and EPS outlook for 2024.

HARP

1 minute read

Why Obesity-Drug Maker NeuroBo Stock Is Trading Higher

By Erica Kollmann

February 1, 11:08 AM

NeuroBo announced that the FDA has cleared its IND application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of 2024.

NRBO

2 minute read

French Pharma Giant Sanofi’s Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs

By Vandana Singh

February 1, 10:24 AM

Sanofi reports Q4 operating income of €2.6B, down 5.2%. Revenues rise 1.8% to €10.92B, Specialty Care grows 13.7%, Dupixent sales surge.

SNY

2 minute read

What’s Going On With Pfizer Stock Today?

By Vandana Singh

February 1, 10:21 AM

Pfizer stock update: Q4 earnings beat expectations with adjusted EPS of $0.10, while FY2023 shows a 72% YoY decline. Explore 2024 R&D plans and recent program discontinuations.

PFE

1 minute read

What’s Going On With Cancer-Focused Corbus Pharmaceuticals Stock Today?

By Vandana Singh

February 1, 10:18 AM

Corbus Pharmaceuticals announces a $82.2M public offering at $19.00 per share. Explore latest updates on CRB-701 clinical study.

CRBP

1 minute read

Acasti Announces Poster Detailing GTX-104 STRIVE-ON Trial

By Benzinga Newsdesk

February 1, 9:39 AM

The poster, Safety and Tolerability of Intravenous Versus Enteral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage, will be presented Thursday February 8th during the Ongoing Clinical Trials session of the

ACST

2 minute read

FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000

By Lara Goldstein

January 31, 8:05 PM

FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address issues in drug development.

JNJ

2 minute read

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer’s, Shifts Focus On Newer Medicines

By Vandana Singh

January 31, 1:10 PM

Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.

BIIB

2 minute read

GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine

By Vandana Singh

January 31, 9:50 AM

GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections.

GSK

2 minute read

Troubled Biotech Company’s Investigational Cancer Drug Gets Greenlighted By FDA

By Benzinga Neuro

January 31, 9:38 AM

This development marks a significant milestone for 23andMe, a company that has been in the spotlight for security breaches in the past.